arrigo de benedetti

Dr. arrigo de benedetti

Department of Biochemistry and Molecular Biology, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA
orcid

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2004 in Oncogene
Verified
Journal Article
Closed access
PDF file
arrigo de benedettiarrigo de benedetti
arrigo de benedetti
JGJeremy R Graff
Jeremy R Graff

1 January 1999 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Closed access
arrigo de benedettiarrigo de benedetti
arrigo de benedetti
DFDavid Favara
David Favara

1 November 1990 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
arrigo de benedettiarrigo de benedetti
arrigo de benedetti
RRR E Rhoads
R E Rhoads
Eukaryotic protein synthesis initiation factor 4E (eIF-4E) is a 25-kDa polypeptide that binds to the 7-methylguanosine-containing cap of mRNA and participates in the transfer of mRNA to the 40S ribosomal subunit, a step that is rate-limiting for protein synthesis under most cellular conditions. eIF-4E is the least abundant of the initiation factors, is present at approximately 10% of molar concentration of mRNA, and thus may serve as a site of regulation for the recruitment of mRNA into polysomes. Previous studies have indicated that phosphorylation of eIF-4E at Ser-53 is correlated with an increased rate of protein synthesis in a variety of systems in vivo and is required for eIF-4E to become bound to the 48S initiation complex. In this study we show that overexpression of eIF-4E in HeLa cells using an episomally replicating, BK virus-based vector leads to an unusual phenotype: cells grow rapidly, forming densely packed, multilayered foci. They progressively form syncytia, some containing as many as six nuclei, and ultimately lyse 1 month after transfection. Some of these properties are reminiscent of oncogenically transformed cells. Cells transfected with the identical vector expressing a variant of eIF-4E, which contains alanine at position 53 and thus cannot be phosphorylated at the major in vivo site, grow normally. Estimations using the Ala-53 variant or a bacterial chloramphenicol acetyltransferase reporter gene in the same vector indicate that the degree of eIF-4E overexpression is 3- to 9-fold more than the endogenous level. These results suggest that eIF-4E may play a key role in cell cycle progression.

31 July 1997 in Oncogene
Verified
Journal Article
Closed access
CNCherie-Ann O Nathan
Cherie-Ann O Nathan
LLLi Liu
Li Liu
BLBenjamin D Li
Benjamin D Li
FAFleurette W Abreo
Fleurette W Abreo
INIndrani Nandy
Indrani Nandy
arrigo de benedettiarrigo de benedetti
arrigo de benedetti

20 February 1995 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
VKVaishali Kerekatte
Vaishali Kerekatte
KSKyle Smiley
Kyle Smiley
BHBei Hu
Bei Hu
ASAlbert Smith
Albert Smith
FGFrank Gelder
Frank Gelder
arrigo de benedettiarrigo de benedetti
arrigo de benedetti

1 January 2000 in British Journal of Cancer
Verified
Journal Article
Open access
JCJ P Crew
J P Crew
SFS Fuggle
S Fuggle
RBR Bicknell
R Bicknell
DCD W Cranston
D W Cranston
arrigo de benedettiarrigo de benedetti
arrigo de benedetti
DFDavid Favara
David Favara
Vascular endothelial growth factor (VEGF) is an important factor mediating tumour angiogenesis. VEGF mRNA is differentially expressed in bladder cancer with high expression in superficial tumours (stage pTa and pT1) contrasting with low expression in muscle invasive tumours (stage > or = pT2). To investigate mechanisms regulating VEGF expression in bladder cancer, VEGF mRNA and protein were measured in normal bladder (n = 12) and primary bladder cancers (n = 57). VEGF protein levels correlated with mRNA expression in normal bladder (r = 0.68, P = 0.02) and bladder cancer (r = 0.46, P = 0.0007). Whilst VEGF mRNA expression was threefold higher in superficial compared to muscle invasive bladder cancers (P = 0.0001) there was no difference in VEGF protein (P = 0.81). Accordingly, the median protein:mRNA ratios increased more than 15-fold with increasing tumour stage (P < 0.0001) suggesting translational regulation. Expression of the eukaryotic initiation factor-4E (elF-4E), a factor implicated in the translational regulation of VEGF, was greater in tumours than normal bladder (P < 0.0001) and correlated with VEGE protein:mRNA ratios (n = 43, r = 0.54, P = 0.0004) pointing to its role in the regulation of VEGF. In superficial tumours (n = 37) high expression of eIF-4E was associated with a poor prognosis and reduced stage progression-free survival (P = 0.04, Cox proportional hazards model). The study demonstrates that eIF-4E may be involved in translational regulation of VEGF in bladder cancer and might have a role as a prognostic factor in bladder cancer.